Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GNFT | US
0.24
4.67%
Healthcare
Biotechnology
31/03/2024
04/10/2024
5.39
5.29
5.39
5.12
Genfit S.A. a biopharmaceutical company discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561 which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ) which is in Phase 1 trial to treat acute-on-chronic liver failure as well as VS-02-HE which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos France.
View LessValue Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
119.2%1 month
87.2%3 months
75.0%6 months
76.2%13.90
7.27
2.62
1.04
0.40
9.07
3.41
-
21.86M
268.80M
268.80M
-
51.00
-
304.40
25.91
12.93
0.12
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.28
Range1M
2.16
Range3M
2.30
Rel. volume
0.19
Price X volume
19.29K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Aviragen Therapeutics Inc | AVIR | Biotechnology | 3.46 | 292.10M | 2.67% | n/a | 0.43% |
THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 5.51 | 291.89M | 5.15% | n/a | 35.68% |
Ocugen Inc | OCGN | Biotechnology | 1.01 | 290.74M | 4.12% | n/a | 40.56% |
Lexeo Therapeutics Inc. Common Stock | LXEO | Biotechnology | 8.66 | 286.31M | -0.69% | n/a | 6.58% |
Design Therapeutics Inc. Common Stock | DSGN | Biotechnology | 5 | 283.10M | 0.60% | n/a | 1.03% |
Rigel Pharmaceuticals Inc | RIGL | Biotechnology | 16.04 | 282.22M | -3.32% | n/a | -201.68% |
Abeona Therapeutics Inc | ABEO | Biotechnology | 6.46 | 279.81M | 3.69% | n/a | 31.63% |
Akebia Therapeutics Inc | AKBA | Biotechnology | 1.33 | 279.68M | -0.75% | n/a | -309.96% |
Nkarta Inc | NKTX | Biotechnology | 3.92 | 279.65M | -6.00% | n/a | 18.88% |
Editas Medicine Inc | EDIT | Biotechnology | 3.38 | 278.77M | 4.97% | n/a | 16.68% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 9.07 | 0.76 | Expensive |
Ent. to Revenue | 3.41 | 3,674.48 | Cheaper |
PE Ratio | 13.90 | 38.01 | Cheaper |
Price to Book | 2.62 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 74.97 | 74.67 | Par |
Debt to Equity | 1.04 | -1.82 | Expensive |
Debt to Assets | 0.40 | 0.26 | Expensive |
Market Cap | 268.80M | 3.73B | Emerging |